- Home
- HQI vs AGEN Comparison
HQI vs AGEN Comparison
Compare HQI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- AGEN
- Stock Information
- Founded
- HQI 2002
- AGEN 1994
- Country
- HQI United States
- AGEN United States
- Employees
- HQI N/A
- AGEN N/A
- Industry
- HQI Professional Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQI Consumer Discretionary
- AGEN Health Care
- Exchange
- HQI Nasdaq
- AGEN Nasdaq
- Market Cap
- HQI 140.2M
- AGEN 142.8M
- IPO Year
- HQI N/A
- AGEN 2000
- Fundamental
- Price
- HQI $9.19
- AGEN $4.15
- Analyst Decision
- HQI Buy
- AGEN Buy
- Analyst Count
- HQI 1
- AGEN 2
- Target Price
- HQI $13.00
- AGEN $14.50
- AVG Volume (30 Days)
- HQI 8.5K
- AGEN 456.4K
- Earning Date
- HQI 11-06-2025
- AGEN 11-11-2025
- Dividend Yield
- HQI 2.62%
- AGEN N/A
- EPS Growth
- HQI N/A
- AGEN N/A
- EPS
- HQI 0.17
- AGEN N/A
- Revenue
- HQI $32,610,000.00
- AGEN $101,706,000.00
- Revenue This Year
- HQI N/A
- AGEN $60.49
- Revenue Next Year
- HQI $1.38
- AGEN N/A
- P/E Ratio
- HQI $52.42
- AGEN N/A
- Revenue Growth
- HQI N/A
- AGEN N/A
- 52 Week Low
- HQI $8.94
- AGEN $1.38
- 52 Week High
- HQI $15.75
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- HQI 34.49
- AGEN 43.11
- Support Level
- HQI $9.12
- AGEN $3.78
- Resistance Level
- HQI $10.23
- AGEN $4.38
- Average True Range (ATR)
- HQI 0.30
- AGEN 0.24
- MACD
- HQI -0.08
- AGEN -0.00
- Stochastic Oscillator
- HQI 0.00
- AGEN 38.24
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).